MXPA05011666A - Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa. - Google Patents

Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.

Info

Publication number
MXPA05011666A
MXPA05011666A MXPA05011666A MXPA05011666A MXPA05011666A MX PA05011666 A MXPA05011666 A MX PA05011666A MX PA05011666 A MXPA05011666 A MX PA05011666A MX PA05011666 A MXPA05011666 A MX PA05011666A MX PA05011666 A MXPA05011666 A MX PA05011666A
Authority
MX
Mexico
Prior art keywords
aryl
kinase inhibitors
compounds useful
amide compounds
substituted pyrazole
Prior art date
Application number
MXPA05011666A
Other languages
English (en)
Inventor
Bang-Chi Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA05011666A publication Critical patent/MXPA05011666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a compuestos que tienen la formula (I), y sales, profarmacos, solvatos, isomeros, y/o hidratos de los mismos farmaceuticamente aceptables, en los cuales Q es un anillo fenilo, priridilo, piridazinilo, pirimidinilo, o pirazinilo opcionalmente substituido; R2 es alquilo o un gupo amino como se define en este documento y Z es oxadiazolilo opcionalmente substituido o -C(&=;O)NR6, en donde R6 es alquilo o ciclopropilo inferior. Los compuestos son sorprendentemente ventajosos en la preparacion de medicamentos para tratar condiciones relacionadas con cinasa p38 y/o en la preparacion de medicamentos para uso en el tratamiento de trastornos o condiciones inflamatorios en un paciente.
MXPA05011666A 2003-05-01 2004-05-03 Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa. MXPA05011666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46702903P 2003-05-01 2003-05-01
PCT/US2004/013604 WO2004099156A1 (en) 2003-05-01 2004-05-03 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05011666A true MXPA05011666A (es) 2005-12-15

Family

ID=33435012

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011666A MXPA05011666A (es) 2003-05-01 2004-05-03 Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.

Country Status (27)

Country Link
US (8) US7151113B2 (es)
EP (5) EP1618092B1 (es)
JP (1) JP4601611B2 (es)
KR (1) KR20060022649A (es)
CN (1) CN1816529A (es)
AT (2) ATE482200T1 (es)
AU (1) AU2004236240C1 (es)
BR (1) BRPI0409949A (es)
CA (1) CA2524321A1 (es)
CO (1) CO5640039A2 (es)
DE (1) DE602004029242D1 (es)
DK (1) DK1618092T3 (es)
ES (3) ES2370463T3 (es)
GE (1) GEP20074236B (es)
HR (1) HRP20100670T1 (es)
IS (1) IS8101A (es)
MX (1) MXPA05011666A (es)
NO (1) NO20054970L (es)
NZ (1) NZ543375A (es)
PL (1) PL1618092T3 (es)
PT (1) PT1618092E (es)
RS (1) RS20050789A (es)
RU (1) RU2342365C2 (es)
SI (1) SI1618092T1 (es)
UA (1) UA81668C2 (es)
WO (3) WO2004099156A1 (es)
ZA (1) ZA200508830B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
DK1618092T3 (da) * 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
WO2005056535A1 (en) * 2003-12-03 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. 1,2,3-triazole amide derivatives as inhibitors of cytokine production
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP4850824B2 (ja) * 2004-03-09 2012-01-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 慢性炎症性疾患の治療のためのサイトカイン生成のインヒビターとしての３−‘４−複素環−１，２，３−トリアゾール−１−イル−ｎ−アリール−ベンズアミド
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
CA2560387C (en) * 2004-05-03 2013-09-24 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
KR20070084172A (ko) 2004-10-12 2007-08-24 아스트라제네카 아베 퀴나졸린 유도체
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
CN101203484B (zh) 2005-06-21 2012-09-05 三井化学株式会社 酰胺衍生物及含有该化合物的杀虫剂
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007052843A1 (ja) * 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
BRPI0620362A2 (pt) * 2005-12-22 2012-07-03 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, métodos para produzir um efeito inibidor de csf-1r quinase em um animal de sangue quente, para produzir um efeito anti-cáncer em um animal de sangue quente e para tratar doença, e, composição farmacêutica
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
DK1999114T3 (en) 2006-03-22 2015-08-03 Hoffmann La Roche Pyrazoles AS 11-BETA-HSD-1
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US8022061B2 (en) 2006-10-10 2011-09-20 Amgen Inc. N-aryl pyrazole compounds, compositions, and methods for their use
US7935696B2 (en) * 2006-10-27 2011-05-03 Bristol-Myers Squibb Company Heterocyclic amide compounds useful as kinase inhibitors
US20100093821A1 (en) * 2006-10-30 2010-04-15 Philipp Holzer 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
JP2010514685A (ja) * 2006-12-20 2010-05-06 ブリストル−マイヤーズ スクイブ カンパニー アリール置換ピラゾールアミド化合物の結晶形
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
WO2008121786A1 (en) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Inhibitors of akt activity
CL2008000979A1 (es) * 2007-04-11 2008-10-17 Sumitomo Chemical Co Proceso para producir un compuesto derivado de 2-piridin-2-il-2h-pirazol-3-fenilamida; compuestos intermediarios; el compuesto en si; composicion plaguicida que contiene a dicho compuesto; uso de dicho compuesto como plaguicida; y metodo para control
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
BRPI0812163A2 (pt) 2007-05-25 2014-12-16 Abbott Gmbh & Co Kg Compostos heterocíclicos como moduladores positivos do receptor metabotrópico de glutamato 2 (receptor mglu2)
BRPI0814825A2 (pt) 2007-07-17 2015-02-03 Hoffmann La Roche Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii
CN101754962B (zh) * 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
WO2009024823A2 (en) 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
US8080546B2 (en) 2007-10-26 2011-12-20 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
EP2210876B1 (en) 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
BRPI0912245A2 (pt) 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
EP2291358B1 (en) * 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP2151434A1 (en) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
MX2011001601A (es) 2008-08-14 2011-03-29 Bayer Cropscience Ag 4-fenil-1h-pirazoles insecticidas.
EP2184273A1 (de) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
EP2379174A4 (en) * 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
PE20100443A1 (es) * 2009-02-06 2010-06-25 Takeda Pharmaceutical Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
JP2013520413A (ja) 2010-02-18 2013-06-06 アストラゼネカ・アクチエボラーグ シクロプロピルアミド誘導体及びそれに関連する中間体の製造方法
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
PE20130405A1 (es) 2010-04-07 2013-04-10 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
WO2012138809A1 (en) * 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
RU2666730C2 (ru) 2012-12-07 2018-09-12 Кемосентрикс, Инк. Диазольные лактамы
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2014100735A2 (en) * 2012-12-21 2014-06-26 Chemocentryx, Inc. Diazole amides
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
CN105324117B (zh) 2013-03-15 2019-04-09 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
WO2014149139A2 (en) * 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3076789A4 (en) * 2013-12-04 2017-11-22 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
JP2017505337A (ja) 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
SI3094329T1 (sl) 2014-01-13 2019-02-28 Aurigene Discovery Technologies Limited Biciklični heterociklilni derivati kot inhibitorji IRAK4
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
BR112016022688B1 (pt) * 2014-04-02 2021-09-08 Bayer Cropscience Aktiengesellschaft Derivados de n-(1-(hetero)aril-1h-pirazol-4-il)-(hetero)arilamida e composições contendo os mesmos
WO2015170218A1 (en) * 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2015173347A1 (de) * 2014-05-14 2015-11-19 At & S Austria Technologie & Systemtechnik Aktiengesellschaft Leiterzug mit verbreiterungsfreiem übergang zwischen leiterbahn und kontaktstruktur
RU2583158C2 (ru) * 2014-06-06 2016-05-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" Метил 5-(арилкарбамоил)-1-(бензил и фенил)-4-циннамоил-1н-пиразол-3-карбоксилаты, проявляющие анальгетическую активность, и способ их получения
EP3157521A4 (en) * 2014-06-20 2018-02-14 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
RU2017112739A (ru) 2014-09-17 2018-10-17 Версеон Корпорейшн Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US11180456B2 (en) * 2015-12-16 2021-11-23 Nippon Soda Co., Ltd. Arylazole compound and pest control agent
RU2745195C2 (ru) 2016-04-07 2021-03-22 Кемосентрикс, Инк. Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
CN110023290B (zh) 2016-09-15 2022-08-12 勃林格殷格翰国际有限公司 作为ripk2抑制剂的杂芳基甲酰胺化合物
ES2946001T3 (es) * 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
MX2019004999A (es) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Derivados biciclo hetorociclicos sustituidos, utiles como inhibidores del canal de potasio medular externo renal (romk).
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
SG11201908171TA (en) 2017-03-31 2019-10-30 Aurigene Discovery Tech Ltd Compounds and compositions for treating hematological disorders
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
HUE067356T2 (hu) 2017-10-31 2024-10-28 Curis Inc IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
CN110028450A (zh) * 2018-01-12 2019-07-19 沈阳中化农药化工研发有限公司 一种吡唑酰胺类化合物的制备方法
CN112313224B (zh) * 2018-04-06 2024-08-13 阿尔托斯实验室公司 Atf6抑制剂和其用途
EP3807266B1 (en) 2018-06-18 2023-10-25 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
BR112020025814A2 (pt) 2018-06-18 2021-04-06 Janssen Pharmaceutica Nv Derivados de pirazol como inibidores de malt1
JP7482122B2 (ja) * 2018-07-03 2024-05-13 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
BR112022000325A2 (pt) 2019-07-11 2022-03-15 Escape Bio Inc Indazois e azaindazois como inibidores de lrrk2
WO2024226603A1 (en) * 2023-04-24 2024-10-31 Regents Of The University Of Minnesota Therapeutic compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134987A (en) * 1976-01-14 1979-01-16 Huppatz John L Compounds and compositions
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPH04316559A (ja) 1990-11-28 1992-11-06 Nissan Chem Ind Ltd ピラゾールカルボキサニリド誘導体及び殺菌剤
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
TW290529B (es) * 1992-12-14 1996-11-11 Asahi Glass Co Ltd
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
AUPO622597A0 (en) * 1997-04-15 1997-05-08 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
NZ502702A (en) * 1997-09-23 2002-10-25 Astrazeneca Ab Amide derivatives for the treatment of diseases mediated by TNF, IL-1, IL-6 or IL-8
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
AU3859999A (en) 1998-05-14 1999-11-29 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CA2340454A1 (en) * 1998-09-25 2000-04-06 Astrazeneca Ab Benzamide derivatives and their use as cytokine derivatives
ATE354569T1 (de) 1998-12-04 2007-03-15 Bristol Myers Squibb Co 3-substituierte-4-arylchinolin-2-on derivate als kaliumkanal- modulatoren
NZ514095A (en) * 1999-02-10 2001-09-28 Welfide Corp Amide compounds and medicinal use thereof
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
ATE296820T1 (de) 1999-06-03 2005-06-15 Teikoku Hormone Mfg Co Ltd Substituierte pyrazol-derivate
FR2795726A1 (fr) * 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
AU1416501A (en) 1999-11-18 2001-05-30 Ajinomoto Co., Inc. Novel phenylalanine derivatives
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6194132B1 (en) * 1999-12-28 2001-02-27 Eastman Kodak Company Photographic element, compound, and process
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US6197492B1 (en) * 1999-12-28 2001-03-06 Eastman Kodak Company Photographic element, compound, and process
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
PL365183A1 (en) * 2000-07-31 2004-12-27 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
WO2002023986A1 (fr) * 2000-08-25 2002-03-28 Sankyo Company, Limited Derives de 4-acylaminopyrazole
WO2002036576A1 (en) 2000-10-30 2002-05-10 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
AU2002305260A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
WO2002096905A1 (en) 2001-06-01 2002-12-05 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
EP1451160B1 (en) 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
AU2002357137A1 (en) 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
US6521395B1 (en) * 2002-01-30 2003-02-18 Eastman Kodak Company Infrared couplers for incorporating and recovering metadata
WO2003064389A1 (fr) 2002-01-31 2003-08-07 Ono Pharmaceutical Co., Ltd. Composes bicycliques contenant de l'azote et medicaments contenant ces composes en tant qu'ingredient actif
EP1553089B1 (en) * 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
WO2004014844A2 (en) 2002-08-09 2004-02-19 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
WO2004035545A2 (en) 2002-10-18 2004-04-29 E.I. Du Pont De Nemours And Company Azolecarboxamide herbicides
AU2003296404A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heterocyclic ppar modulators
DE602004028907D1 (de) 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
DK1618092T3 (da) * 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
WO2004106324A1 (en) 2003-05-27 2004-12-09 E.I. Dupont De Nemours And Company Azolecarboxamide herbicides
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0329572D0 (en) 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20060069132A1 (en) 2004-04-07 2006-03-30 Armel Gregory R Azolecarboxamide herbicides
WO2007002742A1 (en) 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
US20080004278A1 (en) 2008-01-03
NO20054970L (no) 2006-01-11
CN1816529A (zh) 2006-08-09
US20100016320A1 (en) 2010-01-21
PL1618092T3 (pl) 2011-02-28
US7396935B2 (en) 2008-07-08
WO2004098518A3 (en) 2005-01-27
RU2005135162A (ru) 2006-05-10
US20080275092A1 (en) 2008-11-06
RU2342365C2 (ru) 2008-12-27
NZ543375A (en) 2009-05-31
ES2350837T3 (es) 2011-01-27
AU2004236240B2 (en) 2010-06-17
WO2004098518A2 (en) 2004-11-18
DK1618092T3 (da) 2011-01-31
EP1620108A2 (en) 2006-02-01
WO2004098528A2 (en) 2004-11-18
WO2004098528A3 (en) 2005-07-14
IS8101A (is) 2005-10-28
EP2385041B1 (en) 2013-09-18
GEP20074236B (en) 2007-11-12
ATE522525T1 (de) 2011-09-15
EP1618092A1 (en) 2006-01-25
NO20054970D0 (no) 2005-10-26
AU2004236240A1 (en) 2004-11-18
CO5640039A2 (es) 2006-05-31
JP2006525359A (ja) 2006-11-09
RS20050789A (sr) 2008-04-04
US20060247247A1 (en) 2006-11-02
US7253170B2 (en) 2007-08-07
PT1618092E (pt) 2010-11-22
US7414056B2 (en) 2008-08-19
ES2370463T3 (es) 2011-12-16
EP2133348B1 (en) 2011-08-31
EP1617840A2 (en) 2006-01-25
US7390810B2 (en) 2008-06-24
US20050159424A1 (en) 2005-07-21
DE602004029242D1 (en) 2010-11-04
BRPI0409949A (pt) 2006-04-25
CA2524321A1 (en) 2004-11-18
US20080108626A1 (en) 2008-05-08
HRP20100670T1 (hr) 2011-01-31
EP2385041A1 (en) 2011-11-09
US7151113B2 (en) 2006-12-19
ATE482200T1 (de) 2010-10-15
EP1620108B1 (en) 2012-06-06
ZA200508830B (en) 2009-05-27
EP2133348A1 (en) 2009-12-16
US7605273B2 (en) 2009-10-20
US20050004176A1 (en) 2005-01-06
AU2004236240C1 (en) 2010-11-04
UA81668C2 (en) 2008-01-25
KR20060022649A (ko) 2006-03-10
EP1618092B1 (en) 2010-09-22
EP1620108A4 (en) 2008-08-27
US7592338B2 (en) 2009-09-22
SI1618092T1 (sl) 2010-11-30
EP1617840A4 (en) 2008-08-20
WO2004099156A1 (en) 2004-11-18
US20040248853A1 (en) 2004-12-09
JP4601611B2 (ja) 2010-12-22
ES2386784T3 (es) 2012-08-30
EP1618092A4 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
RS20050789A (sr) Aril-supstituisana jedinjenja pirazol-amida pogodna za primenu kao inhibitori kinaze
MY135841A (en) Novel benzodioxoles
MY121778A (en) Benzosulfone derivatives
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
MY146532A (en) Thiazole derivative
UA81453C2 (en) Pyrazolopyridine derivates
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
HRP20070452T3 (en) Sulfonamide derivatives for the treatment of diseases
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
TW200619218A (en) Pyrimidines as PLK inhibitors
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
MY147730A (en) Metabotropic glutamate receptor antagonists
AU2003273475A1 (en) N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy
IL164511A0 (en) Heterocyclic compounds
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
BG108207A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
RS50561B (sr) Derivati sulfonamida za lečenje bolesti
MX2012006962A (es) Inhibidores de la esfingosina quinasa.
EA200601177A1 (ru) Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
DE602007004851D1 (de) A2a-adenosin-rezeptor-antagonisten
TW200730506A (en) Compounds and uses thereof
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
TW200640462A (en) Compounds
IL179171A0 (en) Alkyl substituted indoloquinoxalines

Legal Events

Date Code Title Description
FG Grant or registration